Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

164.60DKK
10:59am EDT
Change (% chg)

kr.-5.45 (-3.20%)
Prev Close
kr.170.05
Open
kr.171.55
Day's High
kr.172.55
Day's Low
kr.164.15
Volume
573,556
Avg. Vol
284,681
52-wk High
kr.444.00
52-wk Low
kr.158.55

Chart for

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.64
Market Cap(Mil.): kr.5,494.41
Shares Outstanding(Mil.): 32.31
Dividend: --
Yield (%): --

Financials

  BAVA.CO Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -4.68 -- --
ROI: -6.27 12.92 12.63
ROE: -6.91 14.94 14.82

BRIEF-Bavarian Nordic FY EBIT Rises To DKK 353.2‍​ Million

* FY EBIT DKK 353.2‍​ MILLION VERSUS DKK 33.0 MILLION YEAR AGO

Mar 12 2018

BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer

* BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER

Mar 08 2018

BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study

* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE

Mar 06 2018

BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab

* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS

Feb 26 2018

Earnings vs. Estimates